CureVac’s Public Market Journey Concludes Following BioNTech Acquisition

CureVac NL0015436031

The independent, publicly traded chapter of CureVac has drawn to a close. The company's shares have ceased trading on the Nasdaq exchange, marking the final step in its acquisition by rival BioNTech. This definitive move concludes a significant period for the biotech firm and shifts the future of its operations and technology entirely under new ownership.

The takeover process reached its critical milestone on December 18, 2025, when BioNTech's tender offer expired. By that date, shareholders had tendered approximately 195.3 million CureVac shares, representing about 86.75% of the company's outstanding stock. Remaining minority stakeholders were subsequently compensated through a mandatory squeeze-out procedure.

The financial terms of the deal, which valued CureVac with an enterprise value of roughly $1.25 billion, were structured as follows:
* Exchange Ratio: 0.05363 BioNTech American Depositary Shares (ADSs) for each share of CureVac.
* Premium: This ratio represented a premium of approximately 55% over CureVac's weighted average share price from June 2025.

Final Steps: Delisting and Deregistration

BioNTech successfully completed the acquisition, with filings to the U.S. Securities and Exchange Commission (SEC) confirming the corporate restructuring was finalized on January 6, 2026. This made BioNTech the sole owner of CureVac's operational business, with legal succession assumed by CureVac Merger B.V.

Consequently, trading in CureVac's stock was suspended prior to market open on January 6. The formal delisting from the Nasdaq was then executed on January 16, 2026. To terminate all reporting obligations with the SEC, the process to deregister the shares has been initiated. This deregistration is expected to become effective 90 days after the requisite forms are filed.

Strategic Integration and Market Impact

CureVac's official website now confirms its new status as part of the BioNTech Group. While day-to-day operations are expected to continue without immediate disruption, the parent company is evaluating the strategic fit and product portfolio of its new subsidiary. This acquisition strengthens BioNTech's competitive position within the intense market for mRNA therapeutics and vaccines.

For investors who remain confident in the Tübingen-based technology, the focus now shifts entirely to BioNTech stock (Ticker: BNTX), where CureVac's assets and research pipelines have been absorbed. The standalone story of CureVac as a listed entity has reached its conclusion.